Insider trade

Officer sold ~$612K of ABBV shares in the open market

Traded Mar 2, 2026 · Filed Mar 3, 2026

AbbVieABBV

~$612K
Reported value · 2,600 sh @ $235.26: 4,619
Holds after · shares reported: +11.0%
stock since the trade · S&P 500 +11.3%, $234.26 → $259.93 on Oct 1

Why it stands out

AbbVie's GC AND SECRETARY sold $612K of AbbVie shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Mar 2, 2026
Reporting period: Not applicable
Filed with the SEC: Mar 3, 2026

Officer$500K–$1M

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$611,676

Shares × reported transaction price

Timing vs results

26 days after results of Feb 4, 2026, 32 days before results of Apr 3, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $234.26 on Mar 2, 2026, within 5% of its 52-week high, after an 8% rise over the previous 30 trading days

52-week range $170.16 (Apr 21, 2025) to $244.38 (Oct 1, 2025), 86% of the way up, from 251 adjusted closes. 30 trading days earlier: $216.75 on Jan 15, 2026. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Skyrizi on Mar 6, 2026, 4 days after this trade.

New use approved (efficacy supplement). Active ingredient: Risankizumab-Rzaa. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	-3.6%	-1.3%	-2.3%
30 days	-12.5%	-3.8%	-8.7%
90 days	-8.8%	+10.9%	-19.7%
180 days	+8.6%	+12.0%	-3.4%

Past results only. Not a forecast.

Source receipt

Record ID: 0001951400-26-000006
Filed / recorded: Mar 3, 2026, 11:10 PM UTC
Added to OQRO: Oct 2, 2026, 3:52 AM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: AbbVie Inc.
Issuer CIK: 1551152
Ticker: ABBV
Reporting person: Perry C Siatis
Relationship: Officer
Officer title: EVP, GC AND SECRETARY
Security: Common Stock, $0.01 par value
Table: Non-derivative (Table I)
Transaction date: Mar 2, 2026
Transaction code: S
Shares / units: 2,600
Price per share: $235.26
Acquired / disposed: Disposed (D)
Shares owned after: 4,619
Ownership form: Direct
Amendment: No

Footnotes from the filing

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $235.14 to $235.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Around the same time

6mo ago

71Derivative units · @ $217.49

Compensation award — excluded from discretionary-purchase analysis.

Why it stands out Official record

6mo ago

155Derivative units · @ $217.49

Compensation award — excluded from discretionary-purchase analysis.

Why it stands out Official record

6mo ago

35Derivative units · @ $217.49

Compensation award — excluded from discretionary-purchase analysis.

Why it stands out Official record